undamentalytics Newsletter
Sign in

Chemed Corp (CHE) stock

Add to watchlist

Add holding +

NYSE: CHE NYSE Health Care Services Next results ~January 29, 2027

B+ Fundamentals grade

Chemed Corp is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$480

Cash-flow model

Base case. Range ~$360–$640 across our lower- and higher-growth cases (0.6%–10.6% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 13% above our base value.

Price used: $542.18, November 2, 2026

Chemed Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
  • Funds268 adding, 243 cuttingOf 66 active managers that changed their stake, 34 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Chemed files

10-Q filed October 29: Chemed

Chemed's revenue over the twelve months to September 2026 reached $2.66bn, a 5.2% rise on the year, an acceleration from the 3.3% growth recorded a quarter earlier. Free-cash-flow margin, however, slipped to 11.1% from 14.2% a year ago. Buybacks have trimmed the diluted share count by 8.3% over the same period, boosting the value attributable to each remaining share. These shifts push the fundamentals grade up from C+ to B+. Our model value sits little changed at $446 a share, well below the current price of $533. At that price, the market appears to be pricing in cash-flow growth of around 8.3% a year for the next five years, notably faster than the 4.5% a year revenue growth actually delivered. The rating stays Hold.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Chemed stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.60bn, up 3.3% on a year earlier, faster than 2.1% a quarter earlier. Free-cash-flow margin fell to 12.5% from 14.6% a year earlier. The diluted share count is down 7.3% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 4 of our 7 financial-health checks. Our cash-flow model value is $429 a share, against a share price of $513. At that price, our model says the market is pricing in about 7.8% a year of cash-flow growth for five years, faster than the 3.9% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 29, 2027 (estimated)

Chemed Corp's trailing-twelve-month revenue grew 5.2% year on year, with a free-cash-flow margin of 11.1%. Where it stands out: change in share count of -8.3% ranks 3 of 39 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$480 per share in the base case (~$360–$640 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 18.0% while net income grew 1.3%: a 19pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 8.3% in a year, so each share owns more of the business.

Things to watch

  • Weakest spot: revenue growth. Revenue growth of 5.2% ranks 27 of 41 health care services companies we cover (median 7.3%).

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
$6.75 against an average estimate of $6.44: beat by 4.9%
Revenue
$691m, up 10.6% on a year earlier
Share reaction
+4.0% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
Next report
October 27, 2026; average EPS estimate $7.32

Chemed's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.4%
  • 1 week+5.7%
  • 1 month+6.8%
  • This year+27.2%
  • 1 year+26.4%
  • 5 years+13.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.7B
Operating margin
13.9%
Net margin
10.6%
EPS (TTM, diluted)
$20.92

Growth

Revenue growth
+5.2%
Change in growth rate
+1.8 pts
Share count change
−8.3%

Cash

Free cash flow (TTM)
$295M
FCF margin
11.1%

Earnings

Last results
October 27, 2026
Next results (est.)
January 29, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Chemed Corp valuation models and calculator

What the price is pricing in

The share price implies about 8.0% a year of cash-flow growth for five years.That is close to the 4.5% a year revenue growth Chemed has delivered.

  • Priced in8.0%
  • Last 12 months5.2%
  • 3 years a year6.1%
  • 5 years a year4.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($539.67, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$480
Price used
$539.67close November 3, 2026
Implied change
▼ 11%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Chemed Corp's free cash flow after stock-based pay with after-tax interest added back ($311M, FY2026 Q3 TTM), growing 6.9% and 5.9% in the next two years (forecasts, guidance and its record), then back to 5.6% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$360–~$640 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Chemed Corp's free cash flow after stock-based pay ( $311M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Chemed Corp as an operating company, with every model that fits that kind of business. Cost of equity 7.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.61 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$480 ~$360–$640 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$500 ~$400–$780 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$640 ~$440–$960 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$360 ~$290–$450 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$490 ~$360–$640 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Chemed Corp with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −26%
  • Revenue growth 5 points higher ▲ +34%
  • Free-cash-flow margin 1 point lower ▼ −9%
  • Last year's free-cash-flow margin change, if it persists ▼ −22%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $327$450$612$825$1103$1462
8.5% $247$336$452$605$803$1059
10% $199$267$357$474$625$819

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$143.43$154.74$235.71$275.81$429.11$521.74$519.78$503.04$577.97$525.32$426.18$542.18
Market value$2.5bn$2.6bn$3.9bn$4.6bn$7.1bn$8.6bn$8.3bn$7.6bn$8.8bn$8.0bn$6.2bn$7.3bn
+ Net debt (− = net cash)$77m$93m$90m$84m$84m−$163m$152m$23m−$264m−$178m−$75m$188m
Enterprise value$2.6bn$2.7bn$4.0bn$4.7bn$7.2bn$8.4bn$8.4bn$7.6bn$8.5bn$7.8bn$6.1bn$7.5bn
Multiples
Price / sales 1.6x1.6x2.4x2.6x3.7x4.1x3.9x3.6x3.9x3.3x2.4x2.7x
Price / earnings 22.7x23.9x40.2x22.5x32.2x26.8x30.8x30.4x32.2x26.4x23.2x25.9x
Price / free cash flow 19.6x27.2x40.2x19.8x28.6x19.9x33.1x30.1x32.1x21.7x18.9x24.8x
EV / EBITDA 11.8x12.6x27.2x16.7x23.7x18.8x21.0x18.9x21.2x18.2x15.1x17.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

68 /100

Moderate moat

How hard Chemed's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 24.9% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 33.3%, moving by 1.9 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median 13.9%; its worst year was 6.7%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 10 of 10 years, at a median 11.4% of revenue.

  • Discipline 15 / 20

    The diluted share count fell 16.4% over five years.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (73 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $25.76 +20% $2.7bn +8%
Next $27.82 +8% $2.9bn +6%

Next year's EPS estimate has moved +1.5% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.1% on 90 days ago. In the last 30 days, 0 analysts raised Chemed Corp's forecast and 1 cut it.

Consensus EPS forecast Chemed Corp, last 90 days
$25.00 $26.00 $27.00 $28.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $25.23 Current fiscal year, 60 days ago: $25.52 Current fiscal year, 30 days ago: $25.49 Current fiscal year, 7 days ago: $25.49 Current fiscal year, Now: $25.76 $25.76 Next fiscal year, 90 days ago: $27.41 Next fiscal year, 60 days ago: $27.52 Next fiscal year, 30 days ago: $27.52 Next fiscal year, 7 days ago: $27.52 Next fiscal year, Now: $27.82 $27.82

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $25.23$27.41
60 days ago $25.52$27.52
30 days ago $25.49$27.52
7 days ago $25.49$27.52
Now $25.76$27.82

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $6.44 $6.75 +4.9%
Jun 2026 $5.60 $6.06 +8.2%
Mar 2026 $5.30 $5.65 +6.6%
Dec 2025 $7.03 $6.42 −8.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 27, 2026

No numeric guidance in Chemed Corp's latest earnings release (filed October 27, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Chemed Corp's revenue by +6.9% next year and +5.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+7.7%, weight 62%) and the company's own record (+5.6%, weight 38%) . How the weights are set.

Analyst recommendations

5 analysts, Oct 2026
Buy360%
Hold240%
Sell00%

Monthly trend

  1. Oct 2026325
  2. Sep 2026235
  3. Aug 2026134

Counts of recommendations published by analysts covering Chemed Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.4%
of tradable shares
Days to cover
3.97
at average volume
Short interest, 1 month
+6%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
1.9%
of shares
Employees
15,811
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +26.4%

$429.01 on October 31, 2025 to $542.18

ThenNowEffect
Revenue (last 12 months) $2.5bn $2.6bn +3.3%
Net margin 11.6% 10.6% −8.3%
P/E multiple 22.0x 27.2x +23.7%
Share count 15m 14m +7.9%

Biggest factor: p/e multiple.

Last 3 years −6.5%

$580.03 on November 3, 2023 to $542.18

ThenNowEffect
Revenue (last 12 months) $2.2bn $2.6bn +18.7%
Net margin 10.4% 10.6% +2.3%
P/E multiple 38.7x 27.2x −29.6%
Share count 15m 14m +9.3%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CHE−0%−3%+15%−9%−19%+27%
Industry peers (median)−3%−28%+6%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CHE58%42%67%58%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CHE−27%−18%−12%−20%−33%−23%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 43% from March 19, 2024 to March 27, 2026. Getting back needed a 75% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$367.60 – $551.99
From 52-week high
−1.8%
vs 50-day average
+5.3%
vs 200-day average
+17.2%
Volatility (1 year)
28%
Beta vs S&P 500
0.01

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.6%
After a week
7 up, 4 down
typical move ±7.4%
After a month
6 up, 5 down
typical move ±8.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 27, 2026 +4.0% +0.9% — —
July 28, 2026 +5.9% −1.3% +6.0% +7.8%
April 23, 2026 +12.9% +0.4% +13.9% +17.7%
February 25, 2026 −15.3% +0.3% −12.2% −20.6%
October 28, 2025 +6.6% +0.3% +0.5% +1.2%
July 29, 2025 −10.6% −0.4% −8.2% −2.2%
April 23, 2025 −5.6% +3.7% +0.3% −3.1%
February 26, 2025 +6.4% −1.5% +8.1% +11.2%
October 29, 2024 −12.0% −0.1% −12.4% −6.1%
July 24, 2024 −0.1% −2.8% +5.3% +5.7%
April 24, 2024 −7.0% −0.4% −8.2% −9.9%
February 27, 2024 +5.1% +0.1% +6.4% +7.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Chemed Corp’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: no liquid put with an effective price at or below fair value.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Chemed Corp in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Chemed Corp
$2.2B $2.3B $2.4B $2.5B $2.6B $2.7B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $2.3B Revenue (TTM), FY24 Q1: $2.3B Revenue (TTM), FY24 Q2: $2.3B Revenue (TTM), FY24 Q3: $2.4B Revenue (TTM), FY24 Q4: $2.4B Revenue (TTM), FY25 Q1: $2.5B Revenue (TTM), FY25 Q2: $2.5B Revenue (TTM), FY25 Q3: $2.5B Revenue (TTM), FY25 Q4: $2.5B Revenue (TTM), FY26 Q1: $2.5B Revenue (TTM), FY26 Q2: $2.6B Revenue (TTM), FY26 Q3: $2.7B $2.7B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $2.3B
FY24 Q1 $2.3B
FY24 Q2 $2.3B
FY24 Q3 $2.4B
FY24 Q4 $2.4B
FY25 Q1 $2.5B
FY25 Q2 $2.5B
FY25 Q3 $2.5B
FY25 Q4 $2.5B
FY26 Q1 $2.5B
FY26 Q2 $2.6B
FY26 Q3 $2.7B
Revenue growth, TTM YoY Chemed Corp
0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 6.1% Revenue growth, TTM YoY, FY24 Q1: 6.0% Revenue growth, TTM YoY, FY24 Q2: 6.8% Revenue growth, TTM YoY, FY24 Q3: 6.8% Revenue growth, TTM YoY, FY24 Q4: 7.4% Revenue growth, TTM YoY, FY25 Q1: 8.5% Revenue growth, TTM YoY, FY25 Q2: 7.6% Revenue growth, TTM YoY, FY25 Q3: 6.5% Revenue growth, TTM YoY, FY25 Q4: 4.1% Revenue growth, TTM YoY, FY26 Q1: 2.1% Revenue growth, TTM YoY, FY26 Q2: 3.3% Revenue growth, TTM YoY, FY26 Q3: 5.2% 5.2%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 6.1%
FY24 Q1 6.0%
FY24 Q2 6.8%
FY24 Q3 6.8%
FY24 Q4 7.4%
FY25 Q1 8.5%
FY25 Q2 7.6%
FY25 Q3 6.5%
FY25 Q4 4.1%
FY26 Q1 2.1%
FY26 Q2 3.3%
FY26 Q3 5.2%
Operating margin (TTM) Chemed Corp
12% 13% 14% 15% 16% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 15.0% Operating margin (TTM), FY24 Q1: 14.8% Operating margin (TTM), FY24 Q2: 15.4% Operating margin (TTM), FY24 Q3: 15.3% Operating margin (TTM), FY24 Q4: 15.1% Operating margin (TTM), FY25 Q1: 15.6% Operating margin (TTM), FY25 Q2: 14.7% Operating margin (TTM), FY25 Q3: 13.9% Operating margin (TTM), FY25 Q4: 13.4% Operating margin (TTM), FY26 Q1: 12.9% Operating margin (TTM), FY26 Q2: 13.5% Operating margin (TTM), FY26 Q3: 13.9% 13.9%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 15.0%
FY24 Q1 14.8%
FY24 Q2 15.4%
FY24 Q3 15.3%
FY24 Q4 15.1%
FY25 Q1 15.6%
FY25 Q2 14.7%
FY25 Q3 13.9%
FY25 Q4 13.4%
FY26 Q1 12.9%
FY26 Q2 13.5%
FY26 Q3 13.9%
FCF margin (TTM) Chemed Corp
6% 8% 10% 12% 14% 16% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 12.1% FCF margin (TTM), FY24 Q1: 13.2% FCF margin (TTM), FY24 Q2: 7.2% FCF margin (TTM), FY24 Q3: 9.3% FCF margin (TTM), FY24 Q4: 11.4% FCF margin (TTM), FY25 Q1: 9.0% FCF margin (TTM), FY25 Q2: 14.6% FCF margin (TTM), FY25 Q3: 14.2% FCF margin (TTM), FY25 Q4: 12.9% FCF margin (TTM), FY26 Q1: 14.8% FCF margin (TTM), FY26 Q2: 12.5% FCF margin (TTM), FY26 Q3: 11.1% 11.1%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 12.1%
FY24 Q1 13.2%
FY24 Q2 7.2%
FY24 Q3 9.3%
FY24 Q4 11.4%
FY25 Q1 9.0%
FY25 Q2 14.6%
FY25 Q3 14.2%
FY25 Q4 12.9%
FY26 Q1 14.8%
FY26 Q2 12.5%
FY26 Q3 11.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Chemed took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $2.5B
  2. Other income $17.5M · 0.7%
  3. Cost of revenue $1.7B · 67.5%
  4. Gross profit $823M · 32.5%
  5. Selling, general and admin $417M · 16.5%
  6. Other operating costs $67.8M · 2.7%
  7. Operating income $338M · 13.4%
  8. Income tax $90.5M · 3.6%
  9. Net income $265M · 10.5%

Shares of revenue. Source: Chemed's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 1,190 1,281 1,356 1,430 1,413 1,456 1,543 1,577 1,667 1,783 1,939 2,080 2,139 2,135 2,264 2,431 2,530 2,661
Gross profit 356 375 385 397 405 422 456 461 516 555 617 701 770 765 799 854 823 893
EBITDA 148 168 179 182 163 199 218 213 149 282 303 446 402 403 401 430 403 433
Operating income 126 144 154 156 133 168 184 179 113 244 257 390 343 343 341 366 338 371
Net income 74 82 86 89 77 99 110 109 98 206 220 319 269 250 273 302 265 282
Diluted EPS $3.24 $3.55 $4.10 $4.62 $4.16 $5.57 $6.33 $6.48 $5.86 $12.23 $13.31 $19.48 $16.85 $16.53 $17.93 $19.89 $18.34 $20.92
Growth (year on year)
Revenue +3.6% +7.6% +5.9% +5.5% −1.2% +3.0% +6.0% +2.2% +5.7% +7.0% +8.7% +7.3% +2.9% −0.2% +6.1% +7.4% +4.1% +5.2%
EBITDA −4.2% +13.5% +6.6% +1.9% −10.8% +22.3% +9.5% −2.1% −30.3% +90.0% +7.1% +47.5% −9.9% +0.1% −0.3% +7.0% −6.2% +5.4%
Operating income −4.9% +13.6% +7.1% +1.8% −14.7% +26.3% +9.5% −3.1% −36.8% +115.5% +5.6% +51.4% −12.0% +0.1% −0.9% +7.6% −7.7% +5.5%
Net income +9.7% +10.9% +5.1% +3.9% −13.5% +28.6% +11.0% −1.4% −9.7% +109.4% +7.0% +45.3% −15.9% −7.0% +9.2% +10.8% −12.2% +1.3%
Diluted EPS +12.5% +9.6% +15.5% +12.7% −10.0% +33.9% +13.6% +2.4% −9.6% +108.7% +8.8% +46.4% −13.5% −1.9% +8.5% +10.9% −7.8% +10.4%
Margins
Gross margin 29.9% 29.2% 28.4% 27.7% 28.6% 29.0% 29.5% 29.3% 31.0% 31.1% 31.9% 33.7% 36.0% 35.8% 35.3% 35.1% 32.5% 33.5%
EBITDA margin 12.4% 13.1% 13.2% 12.8% 11.5% 13.7% 14.1% 13.5% 8.9% 15.8% 15.6% 21.5% 18.8% 18.9% 17.7% 17.7% 15.9% 16.3%
Operating margin 10.6% 11.2% 11.3% 10.9% 9.4% 11.6% 12.0% 11.3% 6.8% 13.7% 13.3% 18.7% 16.0% 16.1% 15.0% 15.1% 13.4% 13.9%
Net margin 6.2% 6.4% 6.3% 6.2% 5.5% 6.8% 7.1% 6.9% 5.9% 11.5% 11.3% 15.4% 12.6% 11.7% 12.0% 12.4% 10.5% 10.6%
Free-cash-flow margin 11.7% 4.7% 10.7% 6.7% 8.6% 4.6% 8.3% 6.1% 5.9% 13.1% 12.8% 20.7% 11.7% 11.8% 12.1% 15.1% 12.9% 11.1%
Cash flow
Cash from operations 161 86 174 132 151 110 172 135 162 287 301 489 309 310 330 417 388 363
Capital spending 21 26 30 35 29 44 44 40 64 53 53 59 59 57 57 50 63 68
Free cash flow 139 60 145 97 122 67 127 96 98 234 248 430 250 253 273 368 325 295
Stock-based pay — 15 14 12 11 10 15 14 16 19 21 27 31 34 41 52 39 —
Free cash flow after stock pay — 45 131 85 111 56 113 82 82 215 227 404 219 219 233 316 287 —
Balance sheet
Cash 112 50 38 70 84 14 15 15 11 5 6 163 33 74 264 178 75 48
Total debt 152 187 187 187 187 148 91 109 101 89 90 — 185 98 — 0 0 236
Net debt (negative = net cash) 40 137 149 117 103 133 77 93 90 84 84 −163 152 23 −264 −178 −75 188
Diluted shares 23m 23m 21m 19m 19m 18m 17m 17m 17m 17m 17m 16m 16m 15m 15m 15m 14m 13m
Returned to shareholders
Dividends 8 12 13 13 14 14 16 16 17 19 20 21 22 22 24 27 32 34
Buybacks 1 109 144 61 93 110 59 102 95 159 93 176 576 115 68 361 432 525
Total returned 9 121 157 74 107 124 75 119 112 178 112 197 598 137 91 388 463 558

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · September 30, 2026
What it owns · $1.7bn
Short-term assets $366mLonger-term assets $1.4bn
What it owes, and who funded it · $1.7bn
Short-term liabilities $331mLonger-term liabilities $526mShareholders' equity $861m
  • Short-term assets cover short-term liabilities $366m of assets due within a year against $331m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $366m short-term assets against $526m of longer-dated liabilities.
  • More cash than debt $48m of cash against $236m of debt.
  • Debt below 40% of shareholders' equity Debt is 27% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 18% to 27% over five years.
  • A year's operating cash flow covers at least 20% of debt $363m of operating cash flow against $236m of debt.
  • Operating profit covers interest at least five times over Operating income of $371m against $5m of interest.

From Chemed Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$525M
Dividends (TTM)
$33.7M
Returned to shareholders
189%
of free cash flow
Buybacks, last 3 fiscal years
$861M
Diluted share count
−8.3%
year over year
Total shareholder yield
7.8%
dividends 0.5% + buybacks 7.4% of market value
Dividend payout ratio
12%
of net income paid out
Sales & admin spending
16.8%
of revenue
Days sales outstanding
35 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated CHE AVAH HIMS PRVA RDNT EVH Median
Revenue, last 12 months $2.7bn $2.6bn $2.6bn $2.4bn $2.3bn $2.1bn $1.2bn
Revenue growth, last 12 months 5.2% 19.5% 28.0% 24.1% 18.9% −4.5% 7.3%
Revenue growth, 3-year average 6.1% 12.4% 53.7% 16.1% 14.1% 8.7% 11.3%
Revenue growth, latest quarter 10.6% 13.7% 38.2% 21.4% 25.0% 46.9% 8.5%
Gross margin 33.5% 32.3% 68.4% — 13.4% 17.2% 27.9%
Operating margin 13.9% 10.5% −6.0% 1.9% 3.1% −20.4% 2.3%
Operating margin, 3-year average 14.4% 7.0% 0.5% 1.2% 4.4% −8.0% 2.3%
Net margin 10.6% 10.6% −5.5% 1.2% −0.9% −24.1% 1.2%
Cash from operations / revenue 13.6% 6.5% 10.2% 5.6% 13.7% 2.6% 6.1%
Free-cash-flow margin 11.1% 6.0% 2.4% 5.6% 3.2% −2.7% 5.1%
Free-cash-flow margin, 3-year average 11.6% 3.2% — 5.2% 3.7% −2.3% 3.6%
Stock pay / revenue — 0.7% 6.0% 3.2% 2.6% 2.0% 1.1%
Change in share count −8.3% 11.4% 0.3% 2.7% 0.1% −2.4% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 5.2% 7.3% 27 of 41
Change in growth rate Growth +1.8pp +1.1pp 18 of 41
Gross margin Profitability 33.5% 29.0% 10 of 27
Operating margin Profitability 13.9% 2.6% 6 of 40
Net margin Profitability 10.6% 1.2% 5 of 41
Free-cash-flow margin Cash generation 11.1% 5.1% 9 of 40
Long-term debt as % of assets Balance sheet 13.7% 27.7% 9 of 31
Change in share count Balance sheet -8.3% 0.4% 3 of 39
Days sales outstanding Balance sheet 35 days 39 days 10 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue YoY
Segment Vitas $1.7B ▲ 7.7%
Segment Roto Rooter $938M ▲ 1.2%

These categories overlap or exclude eliminations, so shares aren't shown.

From Chemed Corp's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$6.3B
Institutions reporting
527
Shares held vs prior quarter
▲ 1.6%
Positions opened / closed
93 / 55

Top buyers and sellers, Q2 2026: 268 institutions bought and 243 sold ; the biggest buyer was AQR Capital Management LLC (+557K shares) and the biggest seller Two Sigma Investments, LP (−279K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $691M 1.5M 11.0% ▲ 11.0%
AQR Capital Management LLC $446M 972K 7.1% ▲ 134.0%
Vanguard Portfolio Management LLC $367M 787K 5.8% ▼ 3.5%
Vanguard Capital Management LLC $282M 604K 4.5% ▼ 5.0%
Acadian Asset Management LLC $211M 453K 3.4% ▲ 47.7%
State Street Corp $207M 445K 3.3% ▼ 3.8%
Geode Capital Management, LLC $193M 414K 3.1% ▲ 0.7%
Jpmorgan Chase & Co $186M 403K 3.0% ▼ 19.5%
Boston Partners $131M 281K 2.1% New
Epoch Investment Partners, Inc. $124M 267K 2.0% ▲ 6.9%
Dimensional Fund Advisors LP $121M 261K 1.9% ▲ 5.1%
TD Asset Management Inc $119M 256K 1.9% ▼ 8.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Chemed Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8.8M 13 trades by 5 insiders · 0% under pre-set plans
Net ▼ $8.8M net selling
Insider Date Trade Shares Price Value
Mcnamara Kevin J president and CEO September 28, 2026 Sell 2,000 $513.45 $1M
Mcnamara Kevin J president and CEO September 18, 2026 Sell 2,000 $501.40 $1M
Mcnamara Kevin J president and CEO August 21, 2026 Sell 2,000 $541.16 $1.1M
Lee Spencer S executive vice president August 21, 2026 Sell 1,000 $541.04 $541,040
Mcnamara Kevin J president and CEO August 3, 2026 Sell 2,000 $539.51 $1.1M
Grace Patrick P Director July 31, 2026 Sell 190 $532.00 $101,080
Lindell Andrea R Director June 9, 2026 Sell 1,347 $447.33 $602,554
Walsh George J Iii Director May 29, 2026 Sell 500 $437.83 $218,915
Grace Patrick P Director May 8, 2026 Sell 60 $425.78 $25,547
Mcnamara Kevin J president and CEO May 1, 2026 Sell 2,000 $421.13 $842,260
Mcnamara Kevin J president and CEO March 27, 2026 Sell 1,500 $369.37 $554,055
Mcnamara Kevin J president and CEO March 12, 2026 Sell 2,000 $403.18 $806,360

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 7 trades and filings

No trades in Chemed Corp disclosed in the last 12 months; 7 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded June 24, 2025, filed August 13, 2025
  • Byron Donalds(R-FL 19):Sale (full), $1,001 - $15,000, traded March 6, 2025, filed April 14, 2025
  • Byron Donalds(R-FL 19):Sale (full), $1,001 - $15,000, traded March 6, 2025, filed April 14, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 29, 2027 estimated from the company's past filing pattern, not announced

  • October 27, 2026
  • July 28, 2026
  • April 23, 2026
  • February 25, 2026
  • October 28, 2025
  • July 29, 2025

Recent SEC filings

Data status

When each part of this page on Chemed Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Chemed Corp in brief

What does Chemed Corp do?
Chemed Corp is a US-listed company in the health care services industry. Its financial year ends in December.
What is Chemed Corp's stock ticker?
Chemed Corp trades under the ticker CHE on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Chemed Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Chemed Corp reported revenue of $2.7B, 5.2% higher than a year earlier, according to its SEC filings.
What is Chemed Corp's free cash flow?
Chemed Corp's free-cash-flow margin is 11.1% of revenue over the trailing twelve months, ranking 9 of the 40 health care services companies we cover.
What is Chemed Corp's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Chemed Corp's free cash flow after stock-based pay gives ~$480 per share in the base case, and ~$360–$640 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Chemed Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., AQR Capital Management LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Chemed Corp buying back stock, and does it pay a dividend?
Chemed Corp spent $525M on share repurchases over the trailing twelve months, and its diluted share count fell 8.3% over the year.
What is Chemed Corp's market cap?
On November 2, 2026, Chemed Corp's market capitalisation was about $7.3B, with a price-to-earnings ratio of 25.9 and net debt of $188M. Market figures come from third-party market data and may be delayed.
Does Chemed Corp pay a dividend?
Yes: Chemed Corp paid $33.7M in dividends over the trailing twelve months, a dividend yield of 0.47% and a payout ratio of 11.9%.
How much debt does Chemed Corp have?
Chemed Corp's debt-to-equity ratio is 27.4%, from its latest balance sheet (18.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Chemed Corp's competitors?
In our Health Care Services peer group, the companies closest to Chemed Corp are Aveanna Healthcare Holdings, Inc., Hims & Hers Health, Inc., Privia Health Group, Inc., Radnet, Inc. and Evolent Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Chemed Corp's.
Are insiders buying or selling Chemed Corp stock?
Over the last 12 months, Chemed Corp's directors and officers reported 0 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.
When is Chemed Corp's next earnings date?
Around January 29, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Chemed Corp announces its own schedule.